COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03401788
Recruitment Status : Active, not recruiting
First Posted : January 17, 2018
Last Update Posted : May 11, 2020
Information provided by (Responsible Party):
Peloton Therapeutics, Inc.

Brief Summary:
This study is designed to investigate PT2977 as a treatment for VHL disease associated RCC.

Condition or disease Intervention/treatment Phase
VHL - Von Hippel-Lindau Syndrome VHL VHL Gene Mutation VHL Syndrome VHL Gene Inactivation VHL-Associated Renal Cell Carcinoma VHL-Associated Clear Cell Renal Cell Carcinoma Drug: PT2977 Phase 2

Detailed Description:
This open-label Phase 2 study will evaluate the efficacy and safety of PT2977 in patients with VHL disease who have at least 1 measurable RCC tumor. PT2977 will be administered orally and treatment will be continuous. Patients will be evaluated radiologically approximately 12 weeks after initiation of treatment and every 12 weeks thereafter while continuing in the study. Changes in VHL disease-associated non-RCC tumors will also be evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Phase 2 Open Label
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma
Actual Study Start Date : May 2, 2018
Estimated Primary Completion Date : March 29, 2022
Estimated Study Completion Date : March 29, 2022

Arm Intervention/treatment
Experimental: Open Label PT2977
PT2977 is a small molecule inhibitor of HIF-2α, which impairs hypoxic and pseudo-hypoxia signaling in cancer cells.
Drug: PT2977
HIF-2α Inhibitor
Other Name: MK-6482

Primary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: 4-5 Years ]
    ORR per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST)

Secondary Outcome Measures :
  1. Duration of response (DOR) [ Time Frame: 4-5 Years ]
  2. Time to response (TTR) [ Time Frame: 4-5 Years ]
  3. Progression-free survival (PFS) [ Time Frame: 4-5 Years ]
  4. Time to Surgery (TTS) [ Time Frame: 4-5 Years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has a diagnosis of von Hippel Lindau disease, based on a germline VHL alteration
  • Has at least 1 measurable solid RCC tumor and no RCC tumor that requires immediate surgical intervention. The diagnosis of RCC can be radiologic (histologic diagnosis not required). Patients may have VHL disease-associated tumors in other organ systems

Exclusion Criteria:

  • Has received prior treatment with PT2977 or another HIF-2α inhibitor
  • Has had any systemic anti-cancer therapy (includes anti-VEGF therapy or any systemic investigational anti-cancer agent)
  • Has an immediate need for surgical intervention for tumor treatment
  • Has evidence of metastatic disease on screening imaging

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03401788

Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Pennsylvania
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States, 19104
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
Vanderbilt Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Aarhus University Hospital
Aarhus, Denmark
Hospital Georges Pompidou
Paris, France
United Kingdom
Cambridge University Hospital
Cambridge, United Kingdom
Sponsors and Collaborators
Peloton Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Peloton Therapeutics, Inc. Identifier: NCT03401788    
Other Study ID Numbers: PT2977-202
MK6482-004 ( Other Identifier: Merck )
First Posted: January 17, 2018    Key Record Dates
Last Update Posted: May 11, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Von Hippel-Lindau Disease
Pathologic Processes
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neurocutaneous Syndromes
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn